comparemela.com

Latest Breaking News On - Chronic illness therapy - Page 7 : comparemela.com

Early Guselkumab PsA Response Linked to Long-Term Quality of Life Improvement

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

Iptacopan Meets Primary End Point of APPOINT-PNH Trial in Paroxysmal Nocturnal Hemoglobinuria

Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

Trial Shows Iptacopan Lowers Need for Blood Transfusion in Almost All Patients With Paroxysmal Nocturnal Hemoglobinuria

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.